Pre-“Complete Response” Deficiency Communication Possible For ANDA Sponsors
This article was originally published in The Pink Sheet Daily
FDA and GPhA nearing agreement that would let generic drug sponsors receive a list of major application deficiencies before the agency issues its “complete response” letter.
You may also be interested in...
Office of Generic Drugs wants to allow project managers to inform sponsors of major deficiencies before ‘complete response’ letter as part of ‘go/no go’ effort.
Howard Sklamberg, currently director of the CDER Office of Compliance, will take over the Office of Global Regulatory Operations and Policy after a year as CDER compliance office director.
Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.